Arkolith/Insider Trading/ITCI/Form 4

Neumann Mark

EVP, Chief Commercial OfficerIntra-Cellular Therapies, Inc. (ITCI) · full profile →Form 4 · filed Apr 2, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
9
1 non-derivative · 8 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 2, 2025Disposed to issuer(D)53K$132.00$7.0M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 2, 2025Disposed to issuer(D)17K——0
Apr 2, 2025Disposed to issuer(D)23K——0
Apr 2, 2025Grant(A)13K—$013K
Apr 2, 2025Disposed to issuer(D)13K——0
Apr 2, 2025Grant(A)9K—$09K
Apr 2, 2025Disposed to issuer(D)9K——0
Apr 2, 2025Disposed to issuer(D)18K——0
Apr 2, 2025Disposed to issuer(D)13K——0

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-049627) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML